Hareth Nahi
Overview
Explore the profile of Hareth Nahi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
4550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrot A, Facon T, Plesner T, Usmani S, Kumar S, Bahlis N, et al.
Eur J Haematol
. 2025 Feb;
PMID: 39952901
Objectives: This final post hoc analysis evaluated patient-reported outcomes from the Phase 3 MAIA study of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) after median 64.5-month follow-up...
2.
Moreau P, Facon T, Usmani S, Bahlis N, Raje N, Plesner T, et al.
Leukemia
. 2025 Jan;
39(3):710-719.
PMID: 39815052
In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival (PFS) and overall survival versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible...
3.
Uttervall K, Tatting L, Lemonakis K, Majd M, Crafoord J, Olsson M, et al.
Cancer Med
. 2024 Apr;
13(8):e7048.
PMID: 38651177
Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug...
4.
Lund T, Gundesen M, Juul Vangsted A, Helleberg C, Haukas E, Silkjaer T, et al.
Blood Cancer J
. 2024 Apr;
14(1):65.
PMID: 38622134
No abstract available.
5.
Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Saily M, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473382
Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment consisted of...
6.
Nahi H, Afram G, Uttervall K, Lockmer S, Tatting L, Gahrton G, et al.
Cancer Med
. 2023 Nov;
12(22):20736-20744.
PMID: 37921243
Background: The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression-free survival (PFS) and overall survival (OS)....
7.
Gundesen M, Asmussen J, Schjesvold F, Juul Vangsted A, Helleberg C, Haukas E, et al.
Blood Cancer J
. 2023 Jul;
13(1):105.
PMID: 37419876
No abstract available.
8.
Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N, et al.
Future Oncol
. 2023 May;
19(13):887-895.
PMID: 37212642
What Is This Summary About?: This is a summary of a clinical trial called MAIA. The trial tested 2 combinations of cancer drugs (daratumumab plus lenalidomide and dexamethasone compared with...
9.
Moreau P, van de Donk N, Nahi H, Oriol A, Nooka A, Martin T, et al.
Future Oncol
. 2023 May;
19(12):811-818.
PMID: 37132225
What Is This Summary About?: This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory...
10.
Dimopoulos M, Oriol A, Nahi H, San-Miguel J, Bahlis N, Usmani S, et al.
J Clin Oncol
. 2023 Jan;
41(8):1590-1599.
PMID: 36599114
Purpose: With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone...